Sanofi Appoints New CEO Following Paul Hudson Departure Amid R&D Setbacks

Sanofi announced a major executive change on February 12, 2026. The Board of Directors convened on February 11 and decided not to renew the mandate of Chief Executive Officer Paul Hudson. The French pharma giant tapped Belén Garijo, M.D., Ph.D., a Spanish business executive who is currently leading Merck KGaA, to officially take over as the face of the company on April 29. 

The move comes as Sanofi grapples with a string of late-stage clinical failures and mounting investor pressure to deliver on its “Play to Win” strategy. Olivier Charmeil, Executive Vice President of General Medicines at Sanofi, will serve as interim CEO during the transition period following Hudson’s final day on February 17.

A Return of Female Leadership to Big Pharma’s Top Tier

The appointment of Garijo marks a significant moment for diversity in the biopharmaceutical industry’s highest echelons. Following the departure of GSK CEO Emma Walmsley earlier this year, who handed the reins to Luke Miels in January, the highest-ranking leaders of the top 10 global pharma companies had momentarily become all-male. The Spanish business executive, who made history in May 2021 as the first woman to lead a DAX 30 (now DAX 40) company in Germany, will become the only female CEO among the top 10 Big Pharmas so far until Julie Kim takes the helm at Takeda Pharmaceuticals this June (provided the Japanese drugmaker regain its top 10 spot).

Sanofi’s board emphasized that Garijo will bring “increased rigor” to the company’s operations. A medical doctor by training with a reputation for operational discipline, Garijo is credited with turning around Merck KGaA’s healthcare business before leading the entire German conglomerate. Her appointment signals a shift from Hudson’s visionary, marketing-led approach to a focus on clinical execution and R&D governance. 

The Early Triumphs of Hudson’s “Play to Win” Strategy

Paul Hudson, former CEO of Novartis Pharmaceuticals, joined the French Big Pharma in 2019 with a clear directive to modernize its corporate culture. He championed the aggressive “Play to Win” strategy. This approach initially yielded remarkable commercial success. By the third quarter of 2023, Sanofi reported 13 consecutive quarters of growth overall and a double-digit growth in its Specialty Care division, heavily driven by the blockbuster immunology drug Dupixent and rare disease treatments.

During this period, Sanofi successfully launched new therapies that bolstered market confidence. The new hemophilia A therapy Altuviiio performed exceptionally well, and the infant RSV antibody Beyfortus generated substantial early revenue shortly after its launch. Leveraging this momentum, Hudson announced the next chapter of the strategy in late 2023. This included the intention to separate the Consumer Healthcare business Opella to focus entirely on innovative medicines. The corporate goal was to unlock up to €2 billion in cost savings and reinvest those funds directly into the biopharma research and development engine.

The AI Ambition Meets Clinical Reality

Beyond structural changes, Sanofi declared an ambitious goal in mid-2023 to become the first pharma company fully powered by artificial intelligence across all its global operations. In fact, starting from 2022, the Paris-based pharma has been engaging in multiple billion-dollar M&A and partnership deals in AI-powered drug discovery. Then in June 2023, the company launched the “plai” application, an internal platform designed to provide real-time data analytics and predictive modeling for supply chain management and clinical trial recruitment. 

Recognizing that internal data management was only the first step in a true digital transformation, Sanofi aggressively expanded its AI ecosystem through H2 2023 and into 2026 by forging high-value strategic alliances aimed at generative drug design. They signed a potential billion-dollar agreement with BioMap to leverage large language models for biologic design and expanded its collaboration with Aqemia to utilize quantum physics algorithms for small molecule discovery. Sanofi further accelerated this digital push in 2024 through a unique tripartite pact with OpenAI and Formation Bio to build customized drug development AI agents. Subsequent investments in QuantHealth’s digital twin technology for clinical trial simulations and a massive $2.56 billion partnership with Earendil Labs in January 2026 to design next-generation autoimmune therapies firmly cemented the company’s commitment to an AI-first research engine.

While these technological investments positioned Sanofi as a digital pioneer, the situation soon turned upside down. Investors increasingly demanded tangible clinical results rather than digital infrastructure promises. The AI narrative struggled to offset the reality of a faltering late-stage clinical pipeline. The “Play to Win” strategy heavily relied on delivering a new wave of innovative medicines to prepare for the eventual loss of Dupixent exclusivity. The internal research engine simply failed to meet these strict expectations.

The Tolebrutinib Collapse 

The tipping point for Hudson’s tenure stems from a severe cascade of pipeline failures over the past three years. One of the most devastating blows involved tolebrutinib. Sanofi acquired this brain-penetrant Bruton’s tyrosine kinase (BTK) inhibitor via the $3.7 billion buyout of Principia Biopharma in August 2020. The asset faced persistent safety hurdles and clinical defeats. On December 15, 2025, Sanofi disclosed that tolebrutinib failed the Phase 3 PERSEUS trial. The small molecule drug missed its primary endpoint of delaying disability progression in primary progressive multiple sclerosis. The regulatory situation deteriorated further when the FDA subsequently rejected the drug for non-relapsing secondary progressive MS. In the Complete Response Letter (CRL) issued on December 23, 2025, regulators cited a severe idiosyncratic liver injury risk and determined that a favorable benefit-risk profile could not be established.

Cascading Pipeline Failures Across Therapeutic Areas 

The neurology setbacks compounded earlier high-profile failures in other core therapeutic areas. In August 2022, Sanofi completely abandoned its breast cancer candidate amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), after it failed both the Phase 2 AMEERA-3 trial and the critical Phase 3 AMEERA-5 trial. This clinical defeat forced the company to dismantle a major pillar of its oncology pipeline and concede the market space to direct competitors. 

More recently, the company scaled back its respiratory ambitions. In early 2026, Sanofi confirmed the deprioritization of its mRNA-based seasonal influenza vaccine program. This decision signaled a strategic retreat in a highly competitive market dominated by agile biotech rivals. Furthermore, on February 2, 2026, the company announced that the investigational glucosylceramide synthase (GCS) inhibitor venglustat failed the Phase 3 PERIDOT trial in Fabry disease, a rare lysosomal storage disorder. 

A closer look at the research cuts highlights the limits of several long-running partnerships. Sanofi confirmed the deprioritization of eclitasertib, ending the last remaining clinical program from a collaboration launched in 2018 with Denali Therapeutics. Additionally, amlitelimab posted mixed trial results, further shaking investor confidence in the broader immunology portfolio.

The Path Forward for Big Pharma

Garijo faces the immense challenge of stabilizing investor confidence while untangling severe R&D bottlenecks. The financial markets reacted swiftly to the sustained underperformance under Hudson. Sanofi shares tumbled in early trading on the Euronext Paris following the announcement, reflecting short-term uncertainty. The stock has significantly underperformed its peers, dropping approximately 12% over the last 12 months. Meanwhile, rivals like Novo Nordisk and Eli Lilly have surged on the back of wildly successful metabolic franchises. 

The looming Dupixent patent cliff requires immediate and decisive action from the new leadership. Garijo brings a strong medical background combined with an operational iron hand and a highly successful turnaround experience at Merck KGaA. These traits provide the exact profile the Sanofi board desires for this critical phase.

Sanofi’s leadership change underscores a ruthless new reality in the biopharma sector. Boards are demonstrating shrinking patience for R&D attrition. The era of the “visionary CEO” is definitively giving way to the era of “the operator CEO”. The market has grown weary of transformation narratives lacking clinical substance, demanding instead rigorous execution and clear regulatory wins.

Author

Richard Chau